<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862430</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1050</article-id><article-id pub-id-type="other">EPV0318</article-id><article-id pub-id-type="pii">S0924933824010502</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Psychopharmacological factor in the course of COVID-19 among psychiatric inpatients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sorokin</surname><given-names>M.</given-names></name><xref rid="aff2384" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Shabelnik</surname><given-names>A.</given-names></name><xref rid="aff2384" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Bocharova</surname><given-names>M.</given-names></name><xref rid="aff2384" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2385" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0906" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lutova</surname><given-names>N.</given-names></name><xref rid="aff2384" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Limankin</surname><given-names>O.</given-names></name><xref rid="aff2386" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff2387" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Azarova</surname><given-names>L.</given-names></name><xref rid="aff2386" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Neznanov</surname><given-names>N.</given-names></name><xref rid="aff2384" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2388" ref-type="aff">
<sup>5</sup>
</xref></contrib></contrib-group><aff id="aff2384"><sup>1</sup><institution>V.M.Bekhterev National Medical Research Centre for Psychiatry and Neurology</institution>, <city>St. Petersburg</city>, <country>Russian Federation</country></aff><aff id="aff2385"><sup>2</sup><institution>King&#x02019;s College London</institution>, <city>London</city>, <country>United Kingdom</country></aff><aff id="aff2386">
<sup>3</sup>
<institution>St. Petersburg Psychiatric Hospital No. 1 named after P.P. Kashchenko</institution>
</aff><aff id="aff2387">
<sup>4</sup>
<institution>North-Western State Medical University named after I.I. Mechnikov</institution>
</aff><aff id="aff2388"><sup>5</sup><institution>FSBEI HE I.P. Pavlov SPbSMU MOH Russia</institution>, <city>St. Petersburg</city>, <country>Russian Federation</country></aff><author-notes><corresp id="cor0906"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1025">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S506</fpage><lpage>S506</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824010502a.pdf"/><abstract><sec id="sec5448"><title>Introduction</title><p>It is known that many psychopharmacological drugs have anti-inflammatory, as well as antibacterial and antiviral effects.</p></sec><sec id="sec5449"><title>Objectives</title><p>To investigate the association between the severity and duration criteria of COVID-19 with psychopharmacotherapy in double-diagnosed patients.</p></sec><sec id="sec5450"><title>Methods</title><p>A total of 169 case histories from a specialized infectious psychiatric department (May 2020 to January 2021) were evaluated. Progression indicators of severe and mild COVID-19, along with the duration of persistent SARS-CoV-2 viral shedding, were assessed in correlation with the administration of antidepressants, antipsychotics, and acid sphingomyelinase inhibitors (FIASMA-active drugs).</p></sec><sec id="sec5451"><title>Results</title><p>The use of any psychotropic agents was associated with a 0.9% increase in the risk of severe&#x000a0;course of COVID-19 for each unit increase in the systemic inflammation index PLR, specifically in patients with intellectual disability (ICD-10 codes F70-79), when compared to patients with schizophrenia (ICD-10 codes F20-29): R&#x000b2;McF=0.138; AIC=181; &#x003c7;&#x000b2;=25.8; df=9; p=0.002. High PLR values and the use of FIASMA-active drugs were associated with prolonged COVID-19 duration, while antidepressant therapy and elevated C-reactive protein levels were associated with a reduced predicted duration of viral shedding in 13.8% of variance: R&#x000b2;=0.0864; AIC=1299; F=5.2(3), p=0.002. Including the nosology of psychiatric disorders in the regression model increased the proportion of explained variance to 22.8%.</p></sec><sec id="sec5452"><title>Conclusions</title><p>Thymoanaleptic therapy for individuals with psychiatric disorders may act as a protective factor against COVID-19. There is no evidence suggesting adverse effects of antipsychotics on the severity and duration of COVID-19. Further research is necessary to investigate the effects of FIASMA-active psychopharmacological agents within nosologically homogeneous groups.</p></sec><sec id="sec5453"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>